by MM360 Staff | Feb 28, 2026 | Publications
Cancers (Basel). 2026 Feb 19;18(4):686. doi: 10.3390/cancers18040686. ABSTRACT Background: B-cell maturation antigen (BCMA) directed therapies have transformed the treatment landscape for relapsed or refractory multiple myeloma (RRMM). Soluble BCMA (sBCMA), a...
by Marisa Wexler, MS | Feb 27, 2026 | Myeloma News
A new blood test powered by artificial intelligence (AI) could offer a life-saving head start for patients at high risk of pancreatic cancer. Clearnote Health has officially launched its enhanced Avantect Pancreatic Cancer Test, a diagnostic tool designed to catch one...
by MM360 Staff | Feb 27, 2026 | Uncategorized
Source: CURE articles Post Content Read More
by MM360 Staff | Feb 27, 2026 | Uncategorized
Source: CURE articles Post Content Read More
by Marisa Wexler, MS | Feb 26, 2026 | Myeloma News
An “immuno-gene” therapy that turns a virus into a cancer-fighting agent has received a fast-track designation from the U.S. Food and Drug Administration (FDA). The experimental treatment, known as SRN-101, is being developed for recurrent high-grade glioma, an...
